MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 03-03-2026
Agilent Technologies Total Assets 2011-2026 | A
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Agilent Technologies
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 10.7 B | 9.63 B | 9.45 B | 8.54 B | 8.43 B | 7.8 B | 7.48 B | 10.8 B | 10.7 B | 10.5 B | 9.06 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.8 B | 7.48 B | 9.38 B |
Quarterly Total Assets Agilent Technologies
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.8 B | 12.7 B | 12.2 B | 11.9 B | 11.8 B | - | - | 10.8 B | 10.3 B | 10.5 B | - | 10.5 B | 9.67 B | 10.7 B | 10.5 B | 10.7 B | 9.5 B | 9.63 B | 9.63 B | 9.46 B | 8.95 B | 9.45 B | 9.45 B | 9.45 B | 8.7 B | 8.56 B | 8.56 B | 8.56 B | 7.87 B | 8.43 B | 8.43 B | 8.43 B | 7.3 B | 7.79 B | 7.79 B | 7.79 B | 7.52 B | 7.48 B | 7.48 B | 7.48 B | 10.6 B | 10.8 B | 10.8 B | 10.8 B | 10.7 B | 10.7 B | 10.7 B | 10.7 B | 9.1 B | 10.5 B | 10.5 B | 10.5 B | 8.04 B | 9.06 B | 9.06 B | 9.06 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 12.8 B | 7.3 B | 9.63 B |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M |  USA |
 |
CareDx, Inc
CDNA
|
413 M | $ 20.81 | 0.05 % | $ 1.11 B | USA |
 |
Co-Diagnostics
CODX
|
24.7 M | $ 1.55 | 1.31 % | $ 2.06 M | USA |
 |
Castle Biosciences
CSTL
|
531 M | $ 24.49 | 1.03 % | $ 680 M | USA |
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Fulgent Genetics
FLGT
|
1.22 B | $ 15.19 | 2.64 % | $ 459 M | USA |
 |
Aspira Women's Health
AWH
|
5.46 M | - | -6.19 % | $ 10.5 M | USA |
 |
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M |  Britain |
 |
Check-Cap Ltd.
CHEK
|
377 K | - | - | $ 9.42 M |  Israel |
 |
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
16.9 B | $ 118.33 | 1.86 % | $ 9.76 B |  Irlanda |
 |
Illumina
ILMN
|
6.3 B | $ 126.74 | 5.29 % | $ 20.2 B | USA |
 |
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
7.14 B | $ 166.97 | 1.91 % | $ 8.28 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | USA |
 |
Lantheus Holdings
LNTH
|
2.23 B | $ 84.62 | 4.25 % | $ 5.71 B | USA |
 |
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
5.86 B | - | - | $ 19.8 B | USA |
 |
Medpace Holdings
MEDP
|
1.98 B | $ 418.66 | 1.23 % | $ 12.1 B | USA |
 |
Guardant Health
GH
|
2.01 B | $ 87.08 | 4.4 % | $ 10.9 B | USA |
 |
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | Israel |
 |
Koninklijke Philips N.V.
PHG
|
26.9 B | $ 26.34 | 2.95 % | $ 20 B |  Niderland |
 |
Myriad Genetics
MYGN
|
707 M | $ 4.75 | 1.5 % | $ 440 M | USA |
 |
Interpace Biosciences
IDXG
|
33.8 M | $ 1.98 | -0.5 % | $ 8.76 M | USA |
 |
NeoGenomics
NEO
|
1.36 B | $ 9.26 | 3.35 % | $ 1.19 B | USA |
 |
QIAGEN N.V.
QGEN
|
6.28 B | - | - | $ 10.6 B | Niderland |
 |
Biomerica
BMRA
|
5.94 M | $ 2.18 | 0.93 % | $ 5.01 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 256.8 | -0.13 % | $ 21.4 B | USA |
 |
National Research Corporation
NRC
|
135 M | $ 16.46 | -0.48 % | $ 368 M | USA |
 |
Celcuity
CELC
|
467 M | $ 121.35 | 1.97 % | $ 5.67 B | USA |
 |
Natera
NTRA
|
1.39 B | $ 206.16 | 5.86 % | $ 20.3 B | USA |
 |
Neogen Corporation
NEOG
|
3.44 B | $ 9.4 | 4.33 % | $ 2.04 B | USA |
 |
Invitae Corporation
NVTA
|
1.95 B | - | - | $ 21.2 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 194.2 | 2.58 % | $ 21.6 B | USA |
 |
OpGen
OPGN
|
9.86 M | - | -16.95 % | $ 1.54 M | USA |
 |
Organovo Holdings
ONVO
|
14.6 M | - | -2.3 % | $ 19.4 M | USA |
 |
PerkinElmer
PKI
|
12.2 B | - | -0.91 % | $ 14.7 B | USA |
 |
Exagen
XGN
|
58 M | $ 2.9 | 5.07 % | $ 62.5 M | USA |
 |
Precipio
PRPO
|
21.3 M | $ 30.9 | 3.21 % | $ 49.6 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 17.0 | 4.68 % | $ 179 M | China |
 |
Personalis
PSNL
|
270 M | $ 5.52 | 9.52 % | $ 327 M | USA |